2021 kolovoz: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with fluoropyrimidine- and platinum-containing treatment.
CHECKMATE-649 (NCT02872116) was a randomised, multicenter, open-label trial that enrolled 1,581 patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma who had previously received no treatment. The Agilent/Dako PD-L1 IHC 28-8 pharmDx test was used to calculate the combined positive score (CPS) for PD-L1. Patients were given nivolumab in combination with chemotherapy (n=789) or chemotherapy alone (n=792), with the following study treatment regimen:
Nivolumab 240 mg svaka dva tjedna s mFOLFOX6 (fluorouracil, leukovorin i oksaliplatin) ili mFOLFOX6 svaka dva tjedna
Svaka 3 tjedna, Nivolumab 360 mg s CapeOX -om (kapecitabinom i oksaliplatinom) ili CapeOX -om.
Progression-free survival (PFS) measured by blinded independent central review and overall survival were the key efficacy outcome measures in patients with PD-L1 CPS 5 (n=955) (OS). For patients with PD-L1 CPS 5, CHECKMATE-649 showed a statistically significant increase in PFS and OS. The median OS in the nivolumab + chemotherapy arm was 14.4 months (95 percent confidence interval: 13.1, 16.2) compared to 11.1 months (95 percent confidence interval: 10.0, 12.1) in the chemotherapy alone arm (HR 0.71; 95 percent confidence interval: 0.61, 0.83; p0.0001). The median PFS in the nivolumab + chemotherapy arm was 7.7 months (95 percent CI: 7.0, 9.2) versus 6.0 months (95 percent CI: 5.6, 6.9) in the chemotherapy alone arm (HR 0.68; 95 percent CI: 0.58, 0.79; p0.0001).
Kao dodatna mjera ishoda učinkovitosti, svi randomizirani pacijenti (n = 1,581), bez obzira na CPS, imali su statistički značajno poboljšanje OS -a, s medijanom OS -a od 13.8 mjeseci (95 posto CI: 12.6, 14.6) u skupini koja je primala nivolumab plus kemoterapiju naspram 11.6 mjeseci (95 posto CI: 10.9, 12.5) u samo skupini kemoterapije (HR 0.80; 95 posto CI: 0.71, 0.90; p = 0.0002).
Periferna neuropatija, mučnina, umor, proljev, povraćanje, smanjeni apetit, bolovi u trbuhu, zatvor i mišićno-koštana bol najčešća su nuspojava (incidencija 20%) primijećena u bolesnika koji su primali nivolumab u kombinaciji s kemoterapijom koja sadrži fluoropirimidin i platinu.
Slijede preporučene doze nivoalumaba:
Svaka tri tjedna uzimajte 360 mg u kombinaciji s tretmanom koji sadrži fluoropirimidin i platinu.
Svaka dva tjedna uzmite 240 mg u kombinaciji s tretmanom koji sadrži fluoropirimidin i platinu.
Referenca: https://www.fda.gov/
Provjerite detalje ovdje.
